Janus Kinase (JAK) Inhibitors Market 2024-2028
The janus kinase (JAK) inhibitors market is forecasted to grow by USD 15573.4 mn during 2023-2028, accelerating at a CAGR of 20.6% during the forecast period. The report on the janus kinase (JAK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of awareness campaigns on autoimmune disorders, application of jak inhibitors in severe chronic indications, and support from growing healthcare insurance industry.
Technavio's janus kinase (JAK) inhibitors market is segmented as below:
- By Application
- Autoimmune disorders
- Oncology
- By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing number of research grants as one of the prime reasons driving the janus kinase (JAK) inhibitors market growth during the next few years. Also, special drug designations and rising number of strategic alliances among market vendors will lead to sizable demand in the market.
The report on the janus kinase (JAK) inhibitors market covers the following areas:
- Janus Kinase (JAK) Inhibitors Market sizing
- Janus Kinase (JAK) Inhibitors Market forecast
- Janus Kinase (JAK) Inhibitors Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading janus kinase (JAK) inhibitors market vendors that include AbbVie Inc., Alexion Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., CTI BioPharma Corp., Eli Lilly and Co., Galapagos NV, Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Novartis AG, Pfizer Inc., Reistone Biopharma Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the janus kinase (JAK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.